Appointments

866.223.8100

Submit a Form

Questions

866.223.8100

Submit a Form

Expand Content

Cancer Clinical Trials Results

IRBCCTitleHospitalStagePhaseDisease
3952 Analysis of Human Bone Marrow from Donors Undergoing a Bone Marrow HarvestMain Campus  Aplastic Anemia, Bone Cancer, Bone Marrow Failure, Leukemia, Acute Lymphoblastic (ALL) , Leukemia, Acute Myeloid (AML), Leukemia, Chronic Lymphocytic (CLL), Leukemia, Chronic Myeloid (CML), Lymphoma, Lymphoma, Hodgkin, Lymphoma, Non - Hodgkin, Multiple Myeloma, Myelodysplastic Syndrome (MDS)
CASE 141213-644Personalized Monitoring of Intravenous Busulfan Dosing for Patients with Lymphoma Undergoing Autologous Stem Cell TransplantationMain Campus  Lymphoma, Lymphoma, Hodgkin, Lymphoma, Non - Hodgkin
CASE 2407CC448A Phase 1 Trial of the Combination of Everolimus (RAD001) and Bortezomib (VELCADE) for Relapsed or Refractory LymphomaFairview, Hillcrest, Main Campus Phase 1, Phase 2Lymphoma, Lymphoma, Hodgkin, Lymphoma, Non - Hodgkin
CASE 2410CC1005A Study of Hematopoietic Stem Cell Supermobilization in Patients with Non-Hodgkin LymphomaMain Campus  Blood & Marrow Transplant (BMT), Lymphoma, Lymphoma, Non - Hodgkin
CASE 5Z08CC610Clinical Trial for Hematologic Malignancies, The Leukemia & Lymphoma Society and Cleveland Clinic Taussig Cancer Center Partnership Tissue AcquisitionBeachwood, Fairview, Hillcrest, Main Campus  Hematologic Malignancy, Lymphoma, Lymphoma, Hodgkin, Lymphoma, Non - Hodgkin
ECOG 141112-690Randomized Phase 2 Four Arm Study In Patients 60 With Previously Untreated Mantle Cell Lymphoma Of Therapy With: Arm A = Rituximab+ Bendamustine Followed By Rituximab Consolidation; Arm B = Rituximab + Bendamustine + Bortezomib Followed By Rituximab Consolidation; Arm C = Rituximab + Bendamustine Followed By Lenalidomide + Rituximab Consolidation; Arm D = Rituximab + Bendamustine + Bortezomib Followed By Lenalidomide + Rituximab ConsolidationBeachwood, Fairview, Hillcrest, Independence, Main Campus, North Coast Cancer, Parma, Strongsville, Wooster Phase 2Lymphoma, Lymphoma, Mantle Cell, Lymphoma, Non - Hodgkin
MLNM 1Y1213-1017A Phase 1 Study of [14C]-MLN9708 to Assess Mass Balance, Pharmacokinetics, and Metabolism in Patients with Advanced Solid Tumors or LymphomaMain Campus Phase 1Lymphoma, Lymphoma, Hodgkin, Lymphoma, Non - Hodgkin, Solid Tumors
NCI 141212-721Phase II Study of Dose-Adjusted EPOCH Rituximab in Adults with Untreated Burkitt Lymphoma, C-Myc Positive Diffuse Large B-Cell Lymphoma and Plasmablastic LymphomaBeachwood, Fairview, Hillcrest, Independence, Main Campus, North Coast Cancer, Parma, Strongsville, Wooster Phase 2Lymphoma, Lymphoma, Hodgkin, Lymphoma, Non - Hodgkin
SEGE 241213-179A randomized, double-blind, placebo-controlled, phase 3 study of brentuximab vedotin and CHP (A + CHP) versus CHOP in the frontline treatment of patients with CD30-positive mature T-cell lymphomasMain Campus Phase 3Lymphoma, Lymphoma, Non - Hodgkin

Cancer Answers & Appointments

Speak with a cancer nurse specialist for appointment assistance and for answers to your questions about cancer locally at 216.444.7923 or toll-free 1.866.223.8100.

Monday through Friday from 8 a.m. – 4:30 p.m. (ET).

Referrals

Resources for medical professionals

  • Outpatient appointment referrals: 216.444.7923 or 866.223.8100
  • Inpatient hospital transfers: 800.553.5056
  • Referring Physician Concierge: 216.444.6196 or 216.312.4910.

Clinical Trials

Search available cancer clinical trials by disease, hospital, phase or number.

This information is provided by Cleveland Clinic and is not intended to replace the medical advice of your doctor or health care provider. Please consult your health care provider for advice about a specific medical condition.

© Copyright 2014 Cleveland Clinic. All rights reserved.